Mersana Therapeutics, Inc. (NASDAQ:MRSN) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 8:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.mersana.com
Earnings Expectation
Mersana Therapeutics, Inc. a biotechnology company, is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share from revenue of $ 0.44 million. Looking ahead, the full year loss are expected at $ 1.3 per share on the revenues of $ 1.58 million.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications.
